| Catch | |
|
94-428 Mokuola St Ste 305a, Waipahu, HI 96797-3302 | |
| (808) 382-5008 | |
| Not Available |
| Full Name | Catch |
|---|---|
| Type | Facility |
| Speciality | Speech-language Pathologist |
| Location | 94-428 Mokuola St Ste 305a, Waipahu, Hawaii |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508235243 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231HA2400X | Audiologist - Assistive Technology Practitioner | ATP2744 (Hawaii) | Secondary |
| 235Z00000X | Speech-language Pathologist | SP 873 (Hawaii) | Primary |
| Provider Name | Judith Nomura |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1265888481 PECOS PAC ID: 9931533601 Enrollment ID: I20200228001494 |
News Archive
Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it has entered into a co-development and commercialization agreement with TopoTarget A/S for Belinostat, a novel histone deacetylase (HDAC) inhibitor.
A collaboration among researchers in Israel and the United States has resulted in the discovery of a new pathway that has broad implications for treating allergic diseases - particularly eosinophil-associated disorders.
electroCore's non invasive vagus nerve stimulation therapy for the prevention and treatment of cluster headache and migraine was reviewed at both the AHS Annual Scottsdale Headache Symposium (Nov 21st to 24th) and the NANS meeting this weekend (Dec 5th to 8th).
Nutrinia, developing therapies to treat rare gastrointestinal disorders, announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for the company's orally-administered drug for treating short bowel syndrome (SBS) in patients of all ages. Nutrinia plans to begin a pivotal clinical trial in this indication.
In research to be presented at the American Society of Hematology (ASH) annual meeting, investigators at Dana-Farber Cancer Institute in Boston offer a new explanation of why chronic lymphocytic leukemia (CLL) tends to recur in the lymph nodes and bone marrow after being cleared from the bloodstream by chemotherapy. Their findings will be reported during in an oral session on Monday, Dec. 6, at 4:45 p.m. in room 315 of the Orange County Convention Center.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Catch Po Box 4156, Kaneohe, HI 96744-8156 Ph: (808) 382-5008 | Catch 94-428 Mokuola St Ste 305a, Waipahu, HI 96797-3302 Ph: (808) 382-5008 |
News Archive
Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it has entered into a co-development and commercialization agreement with TopoTarget A/S for Belinostat, a novel histone deacetylase (HDAC) inhibitor.
A collaboration among researchers in Israel and the United States has resulted in the discovery of a new pathway that has broad implications for treating allergic diseases - particularly eosinophil-associated disorders.
electroCore's non invasive vagus nerve stimulation therapy for the prevention and treatment of cluster headache and migraine was reviewed at both the AHS Annual Scottsdale Headache Symposium (Nov 21st to 24th) and the NANS meeting this weekend (Dec 5th to 8th).
Nutrinia, developing therapies to treat rare gastrointestinal disorders, announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for the company's orally-administered drug for treating short bowel syndrome (SBS) in patients of all ages. Nutrinia plans to begin a pivotal clinical trial in this indication.
In research to be presented at the American Society of Hematology (ASH) annual meeting, investigators at Dana-Farber Cancer Institute in Boston offer a new explanation of why chronic lymphocytic leukemia (CLL) tends to recur in the lymph nodes and bone marrow after being cleared from the bloodstream by chemotherapy. Their findings will be reported during in an oral session on Monday, Dec. 6, at 4:45 p.m. in room 315 of the Orange County Convention Center.
› Verified 6 days ago
Mrs. Jo Ann Saeko Sakai, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 94-1181 Ka Uka Blvd Ste C, Waipahu, HI 96797 Phone: 808-260-9056 Fax: 877-518-7858 | |
Julie Yasutake, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 94-705 Kaaka St, Waipahu, HI 96797 Phone: 808-721-4535 | |
Sullivan Mccallon Friedrich, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 94-1181 Ka Uka Blvd Ste C, Waipahu, HI 96797 Phone: 808-260-9056 | |
Mrs. Kelly Nicole Lund, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 94-1181 Ka Uka Blvd., Ste C, Waipahu, HI 96797 Phone: 808-260-9056 Fax: 808-444-8353 | |
Miss Vanessa Marie Freitas, MA CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 94-144 Farrington Hwy., Suite 115, Waipahu, HI 96797 Phone: 808-678-3814 | |
Bally-hi Therapy Group, Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 94-1021 Lawakua Loop, Waipahu, HI 96797 Phone: 808-620-3994 | |
Miss Michelle Pereira Camacho, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 94-144 Farrington Hwy Ste 115, Waipahu, HI 96797 Phone: 808-678-3637 Fax: 808-678-3820 |